Single-agent rituximab in treatment-refractory or poor prognosis patients with chronic lymphocytic leukemia

References

• Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review (1975–2006), National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2006/ [Last accessed 13 August 2009]
   Google Scholar
• Zelenetz AD, Abramson JS, Advani RH, et al. NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphoma. J Natl Compr Canc Netw 2010;8:288-334
   Google Scholar
• Gribben JG. How I treat CLL up front. Blood 2010;115:187-97
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomized, open-label, Phase 3 trial. Lancet 2010;376:1164-74
   PubMed Web of Science ®Google Scholar
• Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 2008;49:49-56
   PubMed Web of Science ®Google Scholar
• Balducci L. The geriatric cancer patient: equal benefit from equal treatment. Cancer Control 2001;8(2 Suppl):1-25
   PubMedGoogle Scholar
• Eichhorst BF, Busch R, Stilgenbauer S, et al. First line therapy with fludarabine compared to chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009;114:3382-91
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165-70
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute – Working Group 1996 guidelines. Blood 2008;111:5446-56
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86
   PubMed Web of Science ®Google Scholar
• Faderl S, Ferrajoli A, Frankfurt O, et al. Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy. Leukemia 2009;23:457-66
   PubMed Web of Science ®Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-34
   PubMed Web of Science ®Google Scholar
• Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet 2008;371:1017-29
   PubMed Web of Science ®Google Scholar
• Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2004;2004:163-83
   Google Scholar
• Hallek M, Fingerle-Rowson G, Fink A, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood ASH Annual Meeting Abstracts 2008;112: Abstract 325
   Google Scholar
• Hallek M, Fingerle-Rowson G, Fink AM, et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group. Blood ASH Annual Meeting Abstracts 2009;114: Abstract 535
   Google Scholar
• Robak T, Moiseev SI, Dmoszynska A, et al. Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the international randomized Phase III REACH trial. Blood ASH Annual Meeting Abstracts 2008;112: Abstract LBA-1
   Google Scholar
• Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28:1756-65
   PubMed Web of Science ®Google Scholar
• Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616-23
   PubMed Web of Science ®Google Scholar
• Rai KR, Peterson BL, Appelbaum FR, et al. Long-term survival analysis of the North American Intergroup Study C9011 comparing fludarabine (F) and chlorambucil (C) in previously untreated patients with chronic lymphocytic leukemia (CLL). Blood ASH Annual Meeting Abstracts 2009;114: Abstract 536
   Google Scholar
• Hillmen P, Gribben JG, Follows GA, et al. An open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL). Blood ASH Annual Meeting Abstracts 2009;114: Abstract 3428
   Google Scholar
• Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;27:3994-4001
   PubMed Web of Science ®Google Scholar
• Osterborg A, Foa R, Bezares RF, et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 2009;23:1980-8
   PubMed Web of Science ®Google Scholar
• Pluda JM, Venzon DJ, Tosato G, et al. Parameters affecting the development of non-Hodgkin’s lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol 1993;11:1099-107
   PubMed Web of Science ®Google Scholar
• Bonnet F, Balestre E, Thiebaut R, et al. Factors associated with the occurrence of AIDS−related non−Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine cohort, France. Clin Infect Dis 2006;42:411-17
   PubMed Web of Science ®Google Scholar
• Alexandrescu DT, Wiernik PH. Serum globulins as marker of immune restoration after treatment with high-dose rituximab for chronic lymphocytic leukemia. Med Oncol 2008;25:309-14
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003;21:1746-51
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Keating MJ, O’Brien S, et al. Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia. Cancer 2011;117:3182-86
   Google Scholar
• Gentile M, Vigna E, Mazzone C, et al. Rituximab for the treatment of patients with chronic lymphocytic leukemia. Cancer Manag Res 2010;2:71-81
   PubMedGoogle Scholar
• Bryan J, Borthakur G. Role of rituximab in first-line treatment of chronic lymphocytic leukemia. Ther Clin Risk Manag 2010;7:1-11
   PubMed Web of Science ®Google Scholar
• Byrd JC, Murphy T, Howard RS, et al. Rituximab using thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153-64
   PubMed Web of Science ®Google Scholar
• O’Brien S, Osterborg A. Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 2010;10:361-8
   PubMed Web of Science ®Google Scholar
• Bello C, Veliz M, Pinilla-Ibarz J. Ofatumumab in the treatment of low-grade non-Hodgkin’s lymphomas and chronic lymphocytic leukemia. Expert Rev Clin Immunol 2011;7:295-300
   PubMed Web of Science ®Google Scholar
• Nabhan C, Kay NE. The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia. Clin Med Insights Oncol 2011;5:45-53
   PubMedGoogle Scholar